Using advanced experience, medical research progress, and international know-how, the TeamPerMed project empowers the University of Tartu together with Tartu University Hospital to form the independent Centre for Personalised Medicine - TeamPerMed. This Center of Excellence (CoE) will become a multi-disciplinary unit integrating expertise in Genomics, IT, Clinical Medicine, and Socio-Economic Analysis. It will create a scalable framework for developing clinical guidelines and clinical decision support (CDS) tools that can be effectively integrated into EU healthcare systems. With the guidance from the leading expert partners, Erasmus Medical Centre and the University of Helsinki, a vibrant network of associated stakeholders, and the support of EC and the Republic of Estonia, TeamPerMed will become a recognized regional/EU leader in translating genomic and electronic health data to prevent the development of chronic or hereditary disease and offering high-quality personalized medical care. TeamPerMed will stimulate digital transformation in healthcare by using available databases and electronic health records to develop AI tools and protocols effective for prevention/early identification of individual health risks and their consecutive treatment. TeamPerMed CoE intellectual outputs including technology, tools, knowledge, and innovative healthcare practices, will boost Estonia’s and Europe’s competitiveness in the emerging personalised medicine sector, improving the quality of healthcare, prolonging longevity and maximizing health of European citizens, and bringing the advantages of future digital medicine to our citizens already today. The TeamPerMed Center will become an internationally recognized leader in the areas of personalized medicine and customized healthcare contributing directly to a better physical and mental wellbeing and indirectly to social and spiritual wellness, opening the door to a more harmonious society and paving the way for the ‘next generation

Every year, 1.3 million Europeans have a stroke and one million ultimately die of stroke. One third of stroke patients remain dependent on the help of others. The annual costs for stroke care in Europe are estimated at € 64.1 billion. Stroke incidence increases almost exponentially with age, and the personal, societal, and economic burden of stroke is therefore largely driven by its frequent occurrence in the elderly. The elderly have been strongly underrepresented in previous stroke trials and treatment guidelines have no recommendations specific to this important group. Elderly patients are at the highest risk of complications after stroke, such as infections, fever, and dysphagia. These complications are strongly and independently associated with a higher risk of death or dependency. We will perform a pragmatic, randomised, open clinical trial with blinded outcome assessment in 3800 patients with acute stroke aged 66 years or older, to assess whether pharmacological prevention of infections and fever, and early management of dysphagia, will reduce the risk of death, poor functional outcome, and poor quality of life, and lead to reductions in the costs of stroke care throughout Europe. Patients will be randomised using a factorial design to preventive treatment for 4 days with ceftriaxone, paracetamol, and/or metoclopramide, or to ‘standard care’ alone. The primary outcome is functional outcome at 3 months, assessed with the modified Rankin Scale (mRS), and analysed with ordinal logistic regression. The study will have 90% power to detect a statistically significant shift towards a favourable outcome, assuming a 5% absolute increase in the proportion of patients with a good outcome (mRS 0 to 2) in the intervention group, compared with controls. This simple, safe, and generally available treatment strategy has the potential to lead to an annual reduction of over 25 000 elderly Europeans being dead or dependent as a result of stroke, at very low costs.

Cancer- healthcare, research and innovation face core common challenges, such as fragmentation of initiatives and distancing from important stakeholders, requiring coordinated solutions. These challenges are recognized in Horizon Europe’s Cancer Mission Implementation Plan and in Europe’s Beating Cancer Plan. The proposal Establishing of Cancer Mission Hubs: Networks and Synergies (ECHoS) represents a unique opportunity to coordinate R&I and Healthcare actions on cancer with policy-making processes creating transnational communication & collaboration networks aligned with Cancer Mission objectives. Experiences shows that the setup and implementation of innovative health solutions are more likely to be successful when a broad range of stakeholders and decision-makers from the public and private sectors are part of the process. By fostering the creation of National Cancer Mission Hubs (NCMHs) in member states and associated countries ECHoS will create the conditions for organized stakeholders and individual citizens to collaborate and engage in policy dialogues. The implementation of the Cancer Mission objectives will promote more resilient and people-centric healthcare and research systems. ECHoS will produce (i) general models and guidelines for the creation of sustainable NCMHs, (ii) a knowledge exchange programme to support development of NCMHs competences, (iii) impact models and training sets to help efficiently engaging with distinct stakeholders, (iv) a toolkit for synergies to help NCMH engaging in collaborative work with individual European Initiatives, (v) a business continuity model envisaging long-term sustainability of a EU network of NCMHs and (vi) a calendar of events to create awareness on NCMHs and to help closing the gap in citizens’ participation in cancer policy. In summary, ECHoS will create conditions for NCMHs to be Mission Cancer advocates in MS/AC and set the pace for the development of a transnational network of NCMHs in a second phase.

Background: Breast cancer treatment is complex, incorporating all modern day treatment options which means that many different professions are involved in this pathway. However it is widely known that the patients’ care and service pathway associated with breast cancer through early detection, diagnostic procedures and treatments to the follow- up phase is still discontinuous. Cancer detection, diagnosis and care coordination comprise timely and appropriate care, provided by interprofessional team including medical, nursing and allied health professionals. There is a need for this kind of education both at the basic education level of these health care professionals, in-house training of cancer clinics and learning materials for independent continuous professional development (CPD). An online learning package is a great resource to resolve the issue at some level.Objectives, methods to achieve them and outcomes of the project:Objective 1. (IO1) To review and create evidence based knowledge about interprofessional breast cancer care and treatments. For this purpose, methodology of integrative literature review, observational study and qualitative questionnaire study are used. As a result, the project will produce new research knowledge to develop healthcare teachers’ and staff understanding about breast cancer care and therapies.Objective 2: Improving the quality of breast cancer care and therapies and health care staff education related to this.To fulfill this objective, three e-learning modules comprising of 13 ECTS credits are developed by using evidence-based approach. The pedagogical principle with the interprofessional orientation to be used in the e-learning course will also follow the same evidence based approach. Module 1/IO2 focuses on interprofessional aspects of cancer care and treatment (3 ects). Module 2/IO3 focuses on breast cancer treatments and therapies (5 ects) Module 3/IO4 focuses on ensuring patient safety in breast cancer care and therapies (5 ects). Using evidence-based approach in the development and implementation of the e-learningpackages will facilitate the development of life-long learning competences among the students and health care professionals who are taking part of the courses.Objective 3: Testing and implementing the e-learning package at the European level. For this purpose, e-learning modules created in the process will be developed, tested within the partnership, improved based on the feedback obtained from the participants, experts and the steering committee members, and made available as open access resources. This will lead to the most obvious results of the project, which is better competences related to interprofessional co-operation in breast cancer therapeutic phase among the teachers, students and health professionals who take part in the preparation and testing of the educational packages. Also, teaching and training activity C1- an intensive week will be carried out (on site + online) to introduce the course content and usage to potential users of the online course Target groups of project for IO1 to IO4. Inside the partnership: two cancer clinic nurses, biomedical laboratory scientists (n=about 30), higher education institutions staff (n=20) and students (n=about 80 annually) who will be participating, teaching and studying the topics. Outside the partnership, target groups are European (+wider globally) cancer clinics’ staff and higher education institutions teachers and students (n= several thousand in Europe only). At intensive course activity C1, there will be 15 participants who`s expenses are covered by project grant taking part on site + at least 15 participating with their own cost on site and about 10 online. In addition, HESAV (Swiss associate partner) will apply for funding from Swiss national agency Movetia to send 4 to 5 teachers for the Intensive course.Impacts: The most important impact on the participating organizations as well as on other organizations that take the e-learning package in their educational use will be the harmonization of quality and contents of education in the field of interprofessional breast cancer treatment and its safety. The e-learning package linked also to EU EPALE dissemination platform gives open access resources for education also for such educational and health care institutions who otherwise could not afford or for some other reason are not able to have that kind of learning resources. At participant level this means equal possibility for health care professionals like radiation therapists, radiographers, biomedical laboratory scientists and nurses and their educators to acquire competences on e-learning in general, interprofessional breast cancer treatment and how to ensure its safety. In addition, studying from such of e-learning materials increases health care staff and ordering clinical units’ understanding about different phases, procedures, actors and safety issues associated with breast cancer therapeutic phase.